The Interferons

Mechanisms of Action and Clinical Applications

Samuel Baron, Stephen K. Tyring, W. Robert Fleischmann, Dorian H. Coppenhaver, David Niesel, Gary R. Klimpel, G. John Stanton, Thomas K. Hughes

Research output: Contribution to journalArticle

573 Citations (Scopus)

Abstract

The interferons (IFN) are one of the body’s natural defensive responses to such foreign components as microbes, tumors, and antigens. The IFN response begins with the production of the IFN proteins (α, β, and γ), which then induce the antiviral, antimicrobial, antitumor, and immunomodulatory actions of IFN. Recent advances have led to Food and Drug Administration approval of five clinical indications for IFN. Interferon alfa is approved for hairy-cell leukemia, condyloma acuminatum, Kaposi’s sarcoma in the acquired immunodeficiency syndrome, and non-A, non-B (type C) viral hepatitis. Interferon gamma has properties distinctive from those of IFNs α and β and is approved as an immunomodulatory treatment for chronic granulomatous disease. Promising clinical results with IFNs have also been reported for basal cell carcinoma, chronic myelogenous leukemia, cutaneous squamous cell carcinoma, early human immunodeficiency virus infection, hepatitis B, and laryngeal papillomatosis. Future clinical uses of IFNs may emphasize combination therapy with other cytokines, chemotherapy, radiation, surgery, hyperthermia, or hormones.

Original languageEnglish (US)
Pages (from-to)1375-1383
Number of pages9
JournalJAMA: The Journal of the American Medical Association
Volume266
Issue number10
DOIs
StatePublished - Sep 11 1991

Fingerprint

Interferons
Chronic Granulomatous Disease
Drug Approval
Hairy Cell Leukemia
Condylomata Acuminata
Kaposi's Sarcoma
Basal Cell Carcinoma
Neoplasm Antigens
Virus Diseases
United States Food and Drug Administration
Hepatitis C
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hepatitis B
Interferon-alpha
Interferon-gamma
Antiviral Agents
Squamous Cell Carcinoma
Acquired Immunodeficiency Syndrome
Fever
HIV

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Baron, S., Tyring, S. K., Fleischmann, W. R., Coppenhaver, D. H., Niesel, D., Klimpel, G. R., ... Hughes, T. K. (1991). The Interferons: Mechanisms of Action and Clinical Applications. JAMA: The Journal of the American Medical Association, 266(10), 1375-1383. https://doi.org/10.1001/jama.266.10.1375

The Interferons : Mechanisms of Action and Clinical Applications. / Baron, Samuel; Tyring, Stephen K.; Fleischmann, W. Robert; Coppenhaver, Dorian H.; Niesel, David; Klimpel, Gary R.; Stanton, G. John; Hughes, Thomas K.

In: JAMA: The Journal of the American Medical Association, Vol. 266, No. 10, 11.09.1991, p. 1375-1383.

Research output: Contribution to journalArticle

Baron, S, Tyring, SK, Fleischmann, WR, Coppenhaver, DH, Niesel, D, Klimpel, GR, Stanton, GJ & Hughes, TK 1991, 'The Interferons: Mechanisms of Action and Clinical Applications', JAMA: The Journal of the American Medical Association, vol. 266, no. 10, pp. 1375-1383. https://doi.org/10.1001/jama.266.10.1375
Baron, Samuel ; Tyring, Stephen K. ; Fleischmann, W. Robert ; Coppenhaver, Dorian H. ; Niesel, David ; Klimpel, Gary R. ; Stanton, G. John ; Hughes, Thomas K. / The Interferons : Mechanisms of Action and Clinical Applications. In: JAMA: The Journal of the American Medical Association. 1991 ; Vol. 266, No. 10. pp. 1375-1383.
@article{3a0363c0364643649a8770e9251b0bd8,
title = "The Interferons: Mechanisms of Action and Clinical Applications",
abstract = "The interferons (IFN) are one of the body’s natural defensive responses to such foreign components as microbes, tumors, and antigens. The IFN response begins with the production of the IFN proteins (α, β, and γ), which then induce the antiviral, antimicrobial, antitumor, and immunomodulatory actions of IFN. Recent advances have led to Food and Drug Administration approval of five clinical indications for IFN. Interferon alfa is approved for hairy-cell leukemia, condyloma acuminatum, Kaposi’s sarcoma in the acquired immunodeficiency syndrome, and non-A, non-B (type C) viral hepatitis. Interferon gamma has properties distinctive from those of IFNs α and β and is approved as an immunomodulatory treatment for chronic granulomatous disease. Promising clinical results with IFNs have also been reported for basal cell carcinoma, chronic myelogenous leukemia, cutaneous squamous cell carcinoma, early human immunodeficiency virus infection, hepatitis B, and laryngeal papillomatosis. Future clinical uses of IFNs may emphasize combination therapy with other cytokines, chemotherapy, radiation, surgery, hyperthermia, or hormones.",
author = "Samuel Baron and Tyring, {Stephen K.} and Fleischmann, {W. Robert} and Coppenhaver, {Dorian H.} and David Niesel and Klimpel, {Gary R.} and Stanton, {G. John} and Hughes, {Thomas K.}",
year = "1991",
month = "9",
day = "11",
doi = "10.1001/jama.266.10.1375",
language = "English (US)",
volume = "266",
pages = "1375--1383",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - The Interferons

T2 - Mechanisms of Action and Clinical Applications

AU - Baron, Samuel

AU - Tyring, Stephen K.

AU - Fleischmann, W. Robert

AU - Coppenhaver, Dorian H.

AU - Niesel, David

AU - Klimpel, Gary R.

AU - Stanton, G. John

AU - Hughes, Thomas K.

PY - 1991/9/11

Y1 - 1991/9/11

N2 - The interferons (IFN) are one of the body’s natural defensive responses to such foreign components as microbes, tumors, and antigens. The IFN response begins with the production of the IFN proteins (α, β, and γ), which then induce the antiviral, antimicrobial, antitumor, and immunomodulatory actions of IFN. Recent advances have led to Food and Drug Administration approval of five clinical indications for IFN. Interferon alfa is approved for hairy-cell leukemia, condyloma acuminatum, Kaposi’s sarcoma in the acquired immunodeficiency syndrome, and non-A, non-B (type C) viral hepatitis. Interferon gamma has properties distinctive from those of IFNs α and β and is approved as an immunomodulatory treatment for chronic granulomatous disease. Promising clinical results with IFNs have also been reported for basal cell carcinoma, chronic myelogenous leukemia, cutaneous squamous cell carcinoma, early human immunodeficiency virus infection, hepatitis B, and laryngeal papillomatosis. Future clinical uses of IFNs may emphasize combination therapy with other cytokines, chemotherapy, radiation, surgery, hyperthermia, or hormones.

AB - The interferons (IFN) are one of the body’s natural defensive responses to such foreign components as microbes, tumors, and antigens. The IFN response begins with the production of the IFN proteins (α, β, and γ), which then induce the antiviral, antimicrobial, antitumor, and immunomodulatory actions of IFN. Recent advances have led to Food and Drug Administration approval of five clinical indications for IFN. Interferon alfa is approved for hairy-cell leukemia, condyloma acuminatum, Kaposi’s sarcoma in the acquired immunodeficiency syndrome, and non-A, non-B (type C) viral hepatitis. Interferon gamma has properties distinctive from those of IFNs α and β and is approved as an immunomodulatory treatment for chronic granulomatous disease. Promising clinical results with IFNs have also been reported for basal cell carcinoma, chronic myelogenous leukemia, cutaneous squamous cell carcinoma, early human immunodeficiency virus infection, hepatitis B, and laryngeal papillomatosis. Future clinical uses of IFNs may emphasize combination therapy with other cytokines, chemotherapy, radiation, surgery, hyperthermia, or hormones.

UR - http://www.scopus.com/inward/record.url?scp=85047693985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047693985&partnerID=8YFLogxK

U2 - 10.1001/jama.266.10.1375

DO - 10.1001/jama.266.10.1375

M3 - Article

VL - 266

SP - 1375

EP - 1383

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 10

ER -